| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | -0.018 | 0.7 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.016 | 0.7 |
| mRNA | prochlorperazine | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.011 | 0.7 |
| mRNA | BRD-K44224150 | CTRPv2 | pan-cancer | AAC | 0.024 | 0.7 |
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | -0.023 | 0.7 |
| mRNA | MI-1 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
| mRNA | betulinic acid | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |